CLPT ClearPoint Neuro, Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
16:56
Jun 23
Jun 23
Author expresses being a fan of CLPT but does not state a current position or forward-looking.
Author expresses being a fan of CLPT but does not state a current position or forward-looking trade call.
LOW
20:05
Jun 18
Jun 18
Author names these tickers on a personal focus/watchlist alongside a portfolio update.
Author names these tickers on a personal focus/watchlist alongside a portfolio update; no explicit position language or directional thesis attached to any individual name.
LOW
13:51
Jun 17
Jun 17
UniQure news revitalizes ClearPoint Neuro's platform.
Positive news regarding uniQure's study data revitalizes ClearPoint's platform, which was previously delegitimized by the FDA's handling of the AMT-130 study.
MED
14:23
Oct 24
Oct 24
Position closed to take massive profits
The position in CLPT was closed to take profits after a huge win, with further short-term upside above $30 seen as reliant purely on hype.
MED
09:54
Oct 05
Oct 05
Criticizes CLPT's high meme valuation multiples
Criticizes CLPT's high valuation multiples, arguing the brain surgery market lacks the exploding demand needed to justify comparisons to Nvidia.
MED
15:32
Oct 04
Oct 04
CLPT captures small slice of value chain
Compares CLPT's market position to Zeiss, noting it provides unique technology but captures a smaller portion of the value chain.
MED
19:48
Oct 03
Oct 03
Critical enabler for neurodegenerative disease therapies.
Author highlights the company's critical role in enabling and controlling therapies for major neurodegenerative diseases.
MED
18:03
Oct 03
Oct 03
Trims position for portfolio sizing after tripling.
Author trimmed position for portfolio sizing reasons after it nearly tripled, though remains bullish on its path to a $1B market cap.
MED
12:51
Oct 02
Oct 02
Indispensable MedTech partner with massive FCF potential.
Author remains long, arguing the stock is cheap given its indispensable role to 60 partners and potential approvals worth billions in free cash flow.
HIGH
08:48
Sep 25
Sep 25
Strongly invested citing huge platform potential
Author is strongly invested, citing huge potential as a platform for life-changing therapies and viewing it as a great long-term investment.
MED
06:16
Sep 25
Sep 25
Discloses large existing positions and recent additions
Author discloses large existing positions and recent additions across these names in a monthly portfolio update.
MED
10:01
Aug 15
Aug 15
Author holds large CLPT position
Author discloses the stock is among their biggest current positions.
MED
12:06
Aug 11
Aug 11
Speculates on potential revenue-boosting device partnership
Speculates that a potential device partnership and clinical success could significantly boost mid-term revenue and gross margins.
MED
14:21
Jul 14
Jul 14
Author lists largest current portfolio positions
Author discloses these names as their largest current portfolio positions, indicating ongoing bullish conviction and significant capital allocation.
MED
12:13
May 16
May 16
Growth play with strong future potential.
Author views the stock as a compelling growth play where current prices represent the ground floor for future potential, despite weak present fundamentals.
MED
16:47
May 06
May 06
Discloses CLPT as top portfolio holding
Author discloses CLPT as a top portfolio holding by weighting.
MED
15:24
Mar 14
Mar 14
Discloses recent portfolio purchases and additions
Author discloses recent portfolio purchases and additions across multiple names over the past two weeks.
MED
15:01
Feb 28
Feb 28
Immense moat and disruptive advantage in healthcare
Author is highly bullish on the company's immense value proposition, disruptive customer advantage, and strong competitive moat within the healthcare sector.
MED
15:09
Feb 27
Feb 27
Buying the dip for $1B market cap
Author is buying the post-call dip, projecting that the company will eventually reach a one billion dollar market capitalization.
MED
17:58
Feb 25
Feb 25
Discloses large long-term investment position.
Author discloses this ticker as one of their largest current positions and a long-term investment.
MED
09:23
Oct 26
Oct 26
Discloses long positions in medical technology names
Author discloses existing long positions in medical technology names focused on lasers, magnetic stimulation, and imaging.
MED
18:30
Aug 26
Aug 26
CLPT essential for guiding neurological therapies
Bullish on CLPT due to its essential role in guiding developing neurological therapies to their destinations in the brain.
MED
About CLPT Analyst Coverage
Buzzberg tracks CLPT (ClearPoint Neuro, Inc.) across 2 sources. 3 bullish vs 0 bearish calls from 2 analysts. Sentiment: predominantly bullish (14%). 22 total trade ideas tracked. Latest voices: thematictrader, moodywriter13, @MoodyWriter13.